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NUTRITIONAL STATUS OF RENAL 
TRANSPLANT PATIENTS 
A S du Plessis, H Randall, E Escreet, M Holl, M Conradie, 
M R Moosa, D Labadarios, M G Herselman 
Objective. To assess the effect of renal transplantation on the 
nutritional status of patients. 
Design. Prospective descriptive study. 
Setting. Renal Transplant Clinic at Tygerberg Hospital, 
Western Cape. 
Subjects. Fifty-eight renal transplant patients from Tygerberg 
Hospital were enrolled in the study. The sample was 
divided into two groups of 29 patients each: group 1, less 
than 28 months post-transplant; and group 2, more than 28 
months post-transplant. 
Outcome measures. Nutritional status assessment comprised 
biochemical evaluation, a dietary history, anthropometric 
measurements and a clinical examination. 
Results. Serum vitamin B6 levels were below normal in 56% 
of patients from group 1 and 59% from group 2. Vitamin B6 
intake, however, was insufficient in only 14% of patients 
from group 1and10% from group 2. Serum vitamin C 
levels were below normal in 7% of patients from group 1 
and 24% from group 2, while vitamin C intake was 
insufficient in 21%and14% of patients from groups 1 and 2 
respectively. Serum magnesium levels were below normal 
in 55% of patients from group 1, and in 28% from group 2. 
Serum albumin and cholesterol levels increased 
significantly during the post-transplant period in the total 
sample (P = 0.0001). There was also a significant increase in 
body mass index (P = 0.0001) during the post-transplant 
period. 
Conclusions. Several nutritional abnormalities were 
observed, which primarily reflect the side-effects of 
immunosuppressive therapy. The causes, consequences and 
treatment of the vitamin B6 and vitamin C deficiencies in 
renal transplant recipients need further investigation. 
S Afr Med J 2002; 92: 68-74. 
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ORIGINAL ARTICLES 
Chronic renal failure (CRF) is associated with several metabolic 
and nutritional abnormalities such as protein-energy 
malnutrition/' loss of muscle protein,'' abnormal nitrogen 
balance/ vitamin deficiencies or surpluses,9 as well as mineral10 
and lipid abnormalities.11 •12 Although renal transplantation 
improves these abnormalities, the lifelong immunosuppressive 
therapy associated with renal transplantation (usually 
consisting of corticosteroids, cyclosporin and azathioprine) 
adversely affects nutritional status by inducing micronutrient 
deficiencies or surpluses, hypertension, lipid abnormalities, 
obesity, protein catabolism and impaired glycaemic controI.13-16 
This is a matter of concern since the pre-transplant nutritional 
status of most patients is already impaired as a result of CRF 
and the associated dialysis therapy.' The aim of this pilot study 
was to evaluate the nutritional status of renal transplant 
patients at Tygerberg Hospital by means of a dietary history, 
anthropometric measurements, biochemical measurements of 
blood, and a clinical examination. Since data on the vitamin 
status of renal transplant recipients are not readily available, 
special attention was given to this aspect in the nutritional 
assessment. 
SUBJECTS AND METHODS 
The study protocol was approved by the Ethics Committee of 
the Faculty of Medicine, University of Stellenbosch. All patients 
at the Renal Transplant Clinic, Tygerberg Hospital, were 
screened according to the following selection criteria: at least 6 
months post-transplant in order to exclude unstable patients; 
serum creatinine < 200 µmol/l; on daily immunosuppressive 
therapy comprising cyclosporin, low-dose corticosteroids and 
azathioprine; absence of chronic diarrhoea and/or vomiting; 
and no complicating disease that could affect nutritional status. 
Informed consent was obtained from all patients. The median 
of the post-transplant follow-up period was 28 months, and 
this was used to divide the patients into two groups - group 
1, 6 - 28 months post-transplant, and group 2, more than 28 
months post-transplant. There were 29 patients in each group, 
and the groups were comparable with regard to sex, age and 
serum creatinine levels (Table I). The following investigations 
were performed once only on each subject. 
Table I. Description of study groups 
Group 1 Group 2 
(6 - 28 months (> 28 months 
post-transplant) post-transplant) 
Number of patients 
Males (N) 
Females (N) 
Mean age (yrs) (SD) 





35 (13) 41 (16) 
127 (42) 135 (50) 
Biochemical evaluation 
Fasting venous blood samples were obtained for determination 
of the following parameters (using standard laboratory 
techniques): serum levels of albumin (bromcresol green 
method), creatinine, urea, calcium (corrected for serum 
albumin),17 magnesium, potassium, phosphate, and cholesterol; 
plasma pyridoxal-5-phosphate (tyrosine decarboxylase 
apoenzyme activation) and vitamin C (spectrophotometrically); 
and haemoglobin, mean corpuscular haemoglobin (MCH) and 
mean corpuscular volume (MCV). Serum creatinine < 200 
µmo!/! was used as one of the selection criteria. For albumin 
and cholesterol, we also used retrospective measurements 
available for the period immediately before the transplant, in 
order to assess changes after the transplant. Serum cholesterol 
levels were compared with age-adjusted standards for males 
and females (South African Heart Foundation). 
Dietary history 
A quantified food frequency questionnaire (QFFQ), which was 
pre-tested for face validity, was used to determine usual 
dietary intake during the post-transplant period. A single 
observer (A du P) did all assessments. Portion sizes were 
determined by means of food models and the National 
Research Institute for Nutritional Diseases (NRIND) Food 
Quantities Manual,18 and nutrient intake was determined using 
the software package FOODFINDER (South African Medical 
Research Council). Dietary analyses were compared with 
specific recommendations for kidney transplant patients where 
available or the recommended dietary allowances (RDA). 
Protein and energy intake were expressed per kilogram ideal 
body weight. 
Anthropometric measurements 
Body weight was assessed using an electronic platform scale 
which was standardised by means of zero calibration and a 
5 kg weight. Height was determined using a measuring tape 
attached to a wall, as well as a head piece positioned on top of 
the patient's head. Elbow width was measured using a metal 
caliper, triceps skinfold thickness (done in triplicate) using a 
Harpenden skinfold caliper, and mid-arm circumference using 
a non-stretchable measuring tape. Standard measuring 
techniques were used for all anthropometric measurements, 1'"0 
and to avoid the problem of interobserver variation, all 
measurements were taken by a single observer (HR). These 
measurements were used to determine the body mass index 
(BMI) and bone-free arm muscle area. Retrospective 
measurements of body weight for the period immediately 
preceding the transplant were also recorded. 
Clinical examination 
Clinical signs of nutritional deficiencies and the presence of 
oedema were recorded by the same trained investigator (EE). 
lml 
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Biochemical analyses and anthropometric measurements 
were compared with standards for normal, healthy individuals. 
All the information was processed using descriptive statistics 
and unpaired two-sample t-tests where applicable. 
RESULTS 
Biochemical evaluation 
Results of the biochemical determinations are shown in 
Table II. Although mean pre-transplant serum albumin was in 
the low-normal range in both groups, 52% and 62% of patients 
from groups 1 and 2 presented with hypoalbuminaemia. Serum 
albumin levels increased significantly during the post-
transplant period in the group as a whole. The increase in 
serum cholesterol during the post-transplant period was also 
significant for the group as a whole, with no significant 
difference between the groups. Serum cholesterol levels were 
elevated in approximately 10% of patients before the 
transplant, and in 24% of patients during the post-transplant 
period, whereas approximately 30% of patients had low serum 
cholesterol levels before the transplant, compared with only 3% 
of patients from group 1 post-transplant. There was a 
significant correlation between serum cholesterol and BMI 
(r = 0.35, P < 0.01), and age (r = 0.33, P < 0.01). 
Although mean serum calcium levels were within the 
normal range, hypercalcaemia was observed in 3% and 7% of 
patients from groups 1 and 2 respectively during the post-
transplant period, with no patient suffering from 
hypocalcaemia (Table II). Mean serum magnesium levels fell in 
the low-normal range in both groups, with 55% and 28% of 
patients from groups 1 and 2 respectively presenting with 
hypomagnesaemia. Hypophosphataemia and hypokalaemia 
were present in a small number of patients only, although 
mean serum levels generally fell within the normal ranges. 
Mean blood levels of pyridoxal-5-phosphate fell in the low-
normal range. However, more than 55% of all patients had 
marginal vitamin B6 status. Although vitamin C status was 
normal in the majority of patients, 7% of patients from group 1 
and 24% from group 2 had marginal vitamin C status. There 
was no significant difference between the groups for these 
parameters. 
Anaemia was present in 24% of patients from both groups. 
Although iron studies were not available for these patients, a 
hypochromic picture was present in 34% of patients from 
group 1 and 10% from group 2, with a significant difference in 
MCH between the groups (P < 0.01). There was no significant 
difference in MCV between the groups, but MCV was below 
normal in 17% and 3% of patients from groups 1and2, and 
increased in 10% and 14% of patients from groups 1 and 2 
respectively. 
Dietary history 
An increase in appetite was reported in 76% of patients in 
group 1 and 48% in group 2 during the post-transplant period. 
With the exception of 1 patient from group 1, energy intake 
exceeded 130 kJ /kg in all patients, with mean intakes in the 
upper range of the recommendations (Table III). Protein intake 
exceeded the recommended 1 g/kg/ day in 98% of patients. 
The intake of total fat and saturated fat exceeded the 
recommendations in 74% and 75% of patients respectively. 
Micronutrient intake of patients (Table IV) is given as a 
percentage of the RDA (corrected for age and sex), rather than 
actual intake. In contrast with macronutrients, the intake of a 
large number of patients was insufficient for pantothenic acid, 
Table II. Blood values for albumin, cholesterol, selected minerals and vitamins 
Percentage Percentage 
Means (SD) above normal below normal 
Measurement Normal range Total sample Group 1 Group2 Group 1 Group2 Group 1 Group2 
Albumin 
Pre-transplant (g/l) 35-50 34 (7) 36 (8) 33 (7) 0 0 52 62 
Post-transplant Cg/I) 35-50 39 (4)* 40 (5)t 38 (4)t 0 0 7 10 
Cholesterol 
Pre-transplant (mmol/l) 3.8 - 5.7 4.8 (1.3) 4.8 (1.7) 4.8 (1.5) 7 13 29 31 
Post-transplant (mmol/l) 3.8 - 5.7 5.9 (1.4)* 5.7 (1.4) 6.1 (1.4) 24 24 3 0 
Calcium (mmol/l) 2.1 - 2.6 2.4 (0.2) 2.4 (0.1) 2.5 (0.3) 3 7 0 0 
Phosphorus (mmol/ll 0.8 -1.4 1.0 (0.2) 1.0 (0.2) 1.0 (0.2) 0 3 7 14 
Magnesium (mmol/l) 0.75 -1.0 0.7 (0.1) 0.7 (0.1) 0.8 (0.1) 0 3 55 28 
Potassium (mmol/l) 3.5 - 5.3 3.9 (0.5) 3.9 (0.5) 3.8 (0.4) 0 0 14 10 
Pyridoxal-5-P (ng/ml) 6-20 6.8 (5.9) 6.2 (4.0) 7.3 (7.0) 0 3 56 59 
Vitamin C (ng/100 ml) 0.25 - 1.2 0.5 (0.2) 0.5 (0.2) 0.5 (0.3) 0 3 7 24 
•p = 0.0001 (significant increase post-transplant). 
tP = 0.0492 (significant difference between groups 1 and 2). 
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Table III. Daily macronutrient intake of patients (mean (SD)), compared with recommendations for renal transplant recipients" 
Nutrient Recommendation Total sample Group 1 Group 2 
Protein (g/kg) 1.0 1.3 (0.4) 1.4 (0.4) 1.3 (0.4) 
Energy (kJ /kg) 130 -150 153.7 (40.8) 160.2 (40.5) 147 (40.8) 
Carbohydrates 50 50 (9) 51 (9) 50 (9) 
(% of total energy) 
Fat(% of total energy) 30 33 (6) 34 (5) 33 (7) 
Saturated fat < 10 10 (2) 11 (1) 10 (2) 
(%of total energy) 
Polyunsaturated fat < 10 8 (3) 9 (3) 7 (3) 
( % of total energy) 
Cholesterol (mg/ d) < 300 284 (141) 300 (109) 268 (167) 
Table IV. Daily micronutrient intake of patients (mean (SD)), expressed as a percentage of the Recommended Dietary Allowance (RDA) 
Percentage of RDA Percentage of patients < 67% of RDA 
Nutrient 
Riboflavin (mg/d) 
Niacin (mg/ d) 
Pyridoxine (mg/ d) 
Ascorbic acid (mg/ d) 
Folate (mg/ d) 
Pantothenic acid (mg/ d) 
Magnesium (mg/ d) 
Calcium (mg/ d)* 
Phosphorus (mg/ d)* 














Group 2 Group 1 Group 2 
100 (30) 7 14 
~~ 3 7 
178 (32) 14 10 
161 (195) 21 14 
111 (34) 7 3 
82 (26) 24 31 
93 (23) 7 10 
57 (34) 28 45 
~~ 0 0 
144 (38) 0 0 
86 (31) 28 31 
*Intake of calcium and phosphorus expressed as% of recommendations for renal transplant patients (1 200 mg/d each).u· 
calcium and iron. Vitamin B6 intake exceeded the 
recommendations in 62% of patients from group 1 and 55% 
from group 2, and was insufficient in only 14% from group 1 
and 10% from group 2. Similarly, the intake of vitamin C 
exceeded the recommendations in 48% and 31 % of patients 
from groups 1 and 2 respectively, whereas 21 % and 14% had 
insufficient intakes. There were no clinical manifestations of 
vitamin deficiencies. 
Anthropometric measurements 
There was a significant increase in mean BMI from 23 to 25 
kg/m' during the post-transplant period (P = 0.0001) in the 
combined groups, with a large number of patients being 
classified as overweight or obese (Table V). With pre-transplant 
muscle mass data not available, the relative contribution of 
muscle tissue or adiposity to weight gain is unfortunately not 
known. Pitting oedema of the feet and ankles was observed in 
43% of patients from group 1 and 48% from group 2. Because 
of uncertainties regarding the fluid status of patients at the 
time of renal transplantation, we analysed the results of 
patients without oedema at the time of this investigation 
separately. Twenty-six per cent and 43% of patients from 
groups 1 and 2 respectively were still classified as overweight 
or obese. Bone-free arm muscle area was unexpectedly high, 
with 53% of patients from groups 1 and 2 falling above the 90th 
percentile, and none showing signs of depletion (Table VI). 
DISCUSSION 
Malnutrition is an important cause of morbidity and mortality 
among patients on long-term haemodialysis.'1-23 Hypo-
albuminaemia has further been shown to be a strong and 
independent risk factor for all-cause mortality after renal 
transplantation.24 
In this study, visceral protein status before the transplant 
was inadequate, as indicated by the fact that more than 50% of 
patients had pre-transplant serum albumin levels below 35 g/l. 
The significant increase in serum albumin levels post-
transplant may indicate improved nutritional status as a result 
of the increase in appetite as well as improved renal function. 
However, it should also be noted that serum albumin is 
1&11 
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Table V. Anthropometric measurements, expressed as the percentage of patients in each category 
BMI (kg/m2) 
< 16 16 - 16.9 17 - 18.4 18.5 - 24.9 25 - 29.9 30-40 > 40 
Pre-transplant 
Group 1 (N = 28) 0 0 
Group 2 (N = 28) 4 4 
Post-transplant 
Group 1 (N = 28) 0 0 
Group 2 (N = 29) 0 0 
Post-transplant 
(Patients with oedema excluded) 
Group 1 (N = 16) 0 0 
Group 2 (N = 15) 0 0 
Table VI. Bone-free arm muscle area percentiles, expressed as the 
percentage of patients. in each category during the post-transplant 
period 
Bone-free arm muscle area percentiles 
< 15 15- 85 85-95 > 95 
Group 1 (N = 28) 0 36 25 39 
Group2 (N = 29) 0 39 18 43 
Total sample 0 38 22 40 
affected to a large extent by intravascular fluid status. 
Improved renal function post-transplant may therefore lead to 
a reduction in intravascular fluid and hence an increase in 
serum albumin levels, and may falsely suggest improved 
nutritional status.25 The increase in serum albumin may also 
represent a corticosteroid-induced shift of albumin from the 
extravascular to the intravascular space.26 All these factors 
restrict the value of serum albumin as an indicator of 
nutritional status in renal transplant recipients. 
The significant increase in serum cholesterol levels post-
transplant is in agreement with the findings of Kasiske and 
Umen,27 Bumgardner et al.,28 and Vathsala et al.,29 and may 
partly indicate an improvement in nutritional status. However, 
corticosteroids have been shown to induce elevated hepatic 
cholesterol synthesis, which may be related to hyperin-
sulinaemia caused by peripheral insulin resistance," as well as 
depressed activity of adipose tissue lipoprotein lipase.30 
Cyclosporin has also been reported to raise serum cholesterol 
levels, although the mechanism is less certain.31 •32 Others have 
suggested that hyperlipidaemia is not correlated with 
cyclosporin or prednisone dosage but to the degree of obesity,28 
and that patients who do not gain weight post-transplant do 
not have a worsening in lipid profiles.15 In this study we also 
found a significant correlation between BMI and serum 







61 29 4 0 
64 14 4 4 
54 25 21 0 
41 38 0 0 
75 13 13 0 
40 30 13 0 
cholesterol levels. Dietary intake in this study did not comply 
with the step 1 diet and was higher in total and saturated fat 
during the post-transplant period, which may have 
contributed, together with obesity, to the increased serum 
cholesterol levels. The hyperlipidaemia observed in these 
patients may predispose them to cardiovascular disease, a 
major cause of death in many renal transplant recipients. 16 
Although calcium, phosphorus and potassium levels were 
normal in the majority of patients, a small percentage of 
patients presented with hypercalcaemia. This is not an 
unexpected finding and may have been caused by improved 
action of parathyroid hormone and hence bone resorption, 
improved I-hydroxylation of vitamin D,33 as well as steroid-
induced over-secretion of the parathyroid gland. 16 Since bone 
stores may contribute significantly to maintain serum levels in 
cases of magnesium depletion, serum levels of magnesium 
may be normal even in the presence of intracellular 
magnesium depletion. Occurrence of low serum magnesium 
therefore usually indicates significant magnesium deficiency.34 
Low muscle magnesium content has also previously been 
reported in renal transplant recipients.35 Impaired magnesium 
status as reflected by the serum component, is probably due to 
the use of cyclosporin, which has been shown to be 
nephrotoxic, resulting in urinary magnesium loss.36 The 
majority of patients in this study had magnesium intakes 
exceeding the RDA, indicating that the latter might not be 
sufficient for patients on cyclosporin. Since hypomagnesaemia 
is known to produce cardiac arrhythmias and neuromuscular 
irritability, correction of hypomagnesaemia should be 
considered. The hypophosphataemia which occurred in some 
patients may have been caused by a parathyroid hormone 
. excess due to previous renal failure, or a derangement in renal 
phosphate transport. 10•1' Hypophosphataemia may cause 
haemolysis, rhabdomyolysis or central nervous system 
dysfunction at levels below 0.32 mmol/l (I mg/ dl).14 
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The marginal levels of vitamin B6 and vitamin C in a large 
proportion of the study group might be the result of low 
dietary intakes in some patients, as well as the use of 
corticosteroids.37 A previous study also reported a deficiency of 
vitamin B6 in 65% of non-uraemic kidney transplant patients.
38 
However, supplementation of vitamin B6 received no attention 
in the general guidelines for nutritional support of kidney 
transplant patients. The mechanism for deficiency of vitamin B6 
is not known. Vitamin B6 deficiency may be associated with the 
hyperhomocysteinaemia previously described in transplant 
patients,39 and may also lead to impaired neurological function 
and hypochromic microcytic anaemia.40 Although vitamin B6 
supplementation failed to improve plasma total homocysteine 
concentrations, it has been reported to cause a 22% decrease in 
post-methionine-loading increases in plasma homocysteine.41 ,42 
Low plasma levels of vitamin B6 have recently been shown to 
be an independent risk factor for cardiovascular disease, more 
so than increased plasma homocysteine concentrations." 
It has previously been shown that corticosteroids may 
induce urinary loss of vitamin C. 37 An increased demand for 
antioxidant nutrients post-transplant may have contributed to 
low blood levels of vitamin C as well.44 Vitamin C deficiency 
may be associated with anaemia, atherosclerotic plaques and 
pinpoint bleedings." Although the mean dietary intake of 
vitamins B6 and C in our patients was well above the 
recommended limits, quite a number of individual patients 
had suboptimal intake, especially in the case of vitamin C. 
The origin of the anaemia observed in our patients was 
unfortunately not investigated in this study, but iron deficiency 
may have played a role in causing hypochromic microcytic 
anaemia, especially in the light of the low intake of dietary iron 
observed in almost all of our patients, and the rapid expansion 
of the red cell mass following restoration of renal function. The 
possible contributory role of vitamin B6 and vitamin C 
deficiency as a cause of anaemia in some patients should also 
be investigated.'0•45 
An increase in appetite induced by corticosteroids40 could be 
associated with the relatively high energy intake of the study 
group. However, it has been reported by others that post-
transplant weight gain is related mainly to demographic 
factors and not to steroid dosage. 15 An improved sense of 
wellbeing as a result of improved anaemia and renal function 
may also have caused the patients' improvement in appetite. 
The high energy intake of the study group may account for the 
increase in BMI of patients during the post-transplant period. 
Corticosteroids per se may also cause an increase, and a change 
in the distribution of body fat. 46 Because of this corticosteroid-
induced alteration in body fat distribution, body fat 
percentages were not determined in this study. This, together 
with the unavailable data on pre-transplant muscle mass, 
complicated the quantification of fat or muscle tissue as a 
contribution to weight gain. A BMI above 26 has previously 
been shown to reduce graft survival significantly, with the 
effect especially important in those with a BMI exceeding 36."·'8 
Larger people also had a greater need for dialysis in the post-
transplant period. Others have reported that wound infections 
and delayed graft function occurred more commonly in 
moderately and morbidly obese recipients, but there was no 
significant correlation between obesity and graft survival.49 
Modlin et al.'° further reported that obesity per se has little effect 
on long-term graft function, and that outcome differences in 
obese transplant patients were primarily as a result of higher 
mortality from cardiac events. For this reason it is 
recommended that obese patients should not be transplanted 
until weight reduction has been achieved.48•50 
The relatively high bone-free arm muscle area in the 
majority of our patients is unexpected in the light of the 
catabolic effect of corticosteroids, even at low dosages as in this 
study. 1'·1' Miller et al.51 reported that 25 - 50% of their non-
diabetic and diabetic patients respectively presented with mid-
arm muscle circumferences below the 5th percentile 2 years 
post-transplant. Protein and energy intake in their patients 
amounted to 1 g/kg and 105 - 147 kJ/kg respectively, which is 
considerably lower than the intakes of our patients. Harber et 
al.52 also showed that their patients had 20% less mid-thigh 
muscle area as measured by computed tomography. 
Unfortunately they did not report the dietary intake for protein 
and energy, and their results can therefore not be compared 
directly with ours. It seems possible that the relatively high 
protein and energy intakes of our patients may have been 
sufficient to preserve muscle mass. 
CONCLUSION AND RECOMMENDATIONS 
With the exception of some micronutrients, the majority of our 
patients received adequate nutrition during the post-transplant 
period. However, several nutritional abnormalities were 
observed, namely overweight and obesity; increased serum 
cholesterol; and low serum levels of magnesium, vitamin B6 
and vitamin C. Although these abnormalities may partly reflect 
typical side-effects of immunosuppressive therapy, further 
research should explore the mechanisms behind the 
development of the reported nutrient deficiencies. Subsequent 
findings should be used to develop strategies to prevent 
malnutrition and the consequences thereof. 
Vitamin analyses were done by the Department of Human 
Nutrition, University of Stellenbosch and Tygerberg Hospital. 
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